Also found in: Medical, Wikipedia.
Related to pramlintide: Colesevelam, Exenatide, Symlin


An injectable drug that is a synthetic analog of the hormone amylin, used in the form of its acetate salt to treat type 1 and type 2 diabetes.

[pram-, of unknown origin + -lintide, amylin derivative or mimic suffix ((amy)lin + (pep)tide).]


n pramlintida
References in periodicals archive ?
Washington, March 25 ( ANI ): While conducting an experimental model, researchers found that pramlintide, a diabetic drug, helps in reducing amyloid-beta peptides, a major element of Alzheimer's disease (AD) in the brain.
The glucose-lowering drug pramlintide will now be available in pens, but only for patients using premeal bolus insulin.
Some drugs in these classes already have been approved, most notably the incretin mimetic exenatide (Byetta), an inhaled insulin (Exubera), and the amylin analogue pramlintide (Symlin).
Nasdaq: AMLN) and partner Takeda Pharmaceutical Company Limited recently announced that they intend to advance their obesity combination treatment of pramlintide and metreleptin into phase III studies.
Pramlintide acetate as adjunctive therapy for insulin-treated diabetes was considered to not be approvable at this time by a Food and Drug Administration advisory panel.
In July 2009, Amylin presented phase II data from a phase II study in 149 patients testing pramlintide / metreleptin vs.
Amylin's pramlintide acetate (Symlin) recently received approval as an adjunct therapy in combination with insulin for patients with type 1 diabetes.
Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that they are discontinuing development of pramlintide/metreleptin, an investigational combination therapy for the treatment of obesity that comprises pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the natural hormone leptin.
A second poster entitled, "Effects of Pramlintide in Patients with Type 2 Diabetes Mellitus Using Larger Doses of Insulin: A Tertile Analysis Based on Daily Insulin Dose," (poster 1063-P) will also be presented by researchers at ADA.
Poster: "Effects of Pramlintide in Patients with T2DM Using Larger Doses of Insulin - A Tertile Analysis Based on Daily Insulin Dose" will be presented by Kathrin Herrmann, Ph.
The complaint alleges that on July 25, 2001, the Food and Drug Administration ("FDA") released medical and statistical reviews regarding Amylin's diabetes drug pramlintide acetate (SYMLIN) prior to an FDA Advisory Committee Meeting scheduled for July 26, 2001.
To date, approximately 8,000 individuals have received pramlintide in clinical trials, including more than 950 in obesity studies.